ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 173 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $127 | -78.8% | 11,404 | -59.3% | 0.00% | -100.0% |
| Q2 2023 | $600 | -49.1% | 28,009 | -4.0% | 0.00% | -66.7% |
| Q1 2023 | $1,178 | -16.4% | 29,185 | -3.6% | 0.00% | -25.0% |
| Q4 2022 | $1,409 | -99.9% | 30,264 | +28.4% | 0.00% | +33.3% |
| Q3 2022 | $1,221,000 | +43.1% | 23,573 | +30.7% | 0.00% | +50.0% |
| Q2 2022 | $853,000 | -26.2% | 18,034 | +14.0% | 0.00% | 0.0% |
| Q1 2022 | $1,156,000 | -2.2% | 15,823 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $1,182,000 | +31.9% | 15,806 | +0.6% | 0.00% | 0.0% |
| Q3 2021 | $896,000 | +29.5% | 15,714 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $692,000 | -10.0% | 15,714 | +0.2% | 0.00% | 0.0% |
| Q1 2021 | $769,000 | +5.5% | 15,681 | -9.4% | 0.00% | +100.0% |
| Q4 2020 | $729,000 | -19.4% | 17,317 | -12.3% | 0.00% | -50.0% |
| Q3 2020 | $904,000 | -10.3% | 19,754 | -1.8% | 0.00% | 0.0% |
| Q2 2020 | $1,008,000 | -3.6% | 20,119 | -1.4% | 0.00% | -33.3% |
| Q1 2020 | $1,046,000 | -12.4% | 20,398 | +4.7% | 0.00% | 0.0% |
| Q4 2019 | $1,194,000 | -32.4% | 19,487 | -7.0% | 0.00% | -25.0% |
| Q2 2019 | $1,766,000 | -11.2% | 20,952 | +0.6% | 0.00% | -20.0% |
| Q1 2019 | $1,989,000 | +51.4% | 20,828 | +3.6% | 0.01% | +25.0% |
| Q4 2018 | $1,314,000 | -16.6% | 20,109 | +9.0% | 0.00% | 0.0% |
| Q3 2018 | $1,575,000 | -26.3% | 18,452 | 0.0% | 0.00% | -20.0% |
| Q2 2018 | $2,138,000 | +42.0% | 18,452 | -0.9% | 0.01% | +25.0% |
| Q1 2018 | $1,506,000 | +29.5% | 18,617 | -6.1% | 0.00% | +33.3% |
| Q4 2017 | $1,163,000 | +16.0% | 19,835 | -9.0% | 0.00% | +50.0% |
| Q3 2017 | $1,003,000 | +48.4% | 21,791 | +16.0% | 0.00% | 0.0% |
| Q2 2017 | $676,000 | +16.8% | 18,785 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $579,000 | +0.5% | 18,785 | +9.3% | 0.00% | 0.0% |
| Q4 2016 | $576,000 | -37.0% | 17,185 | -50.0% | 0.00% | +100.0% |
| Q3 2016 | $914,000 | +157.5% | 34,370 | +113.3% | 0.00% | 0.0% |
| Q2 2016 | $355,000 | – | 16,117 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |